Roche ’s Hemlibra provided sustained bleed control in the largest pivotal study to date of children with haemophilia A with factor VIII inhibitors

Roche today announced data from the primary analysis of the phase III HAVEN 2 study evaluating Hemlibra ® (emicizumab) prophylaxis in children younger than 12 years of age with haemophilia A with factor VIII inhibitors, including longer follow-up for once-weekly dosing and new data for less frequent dosing schedules (every two weeks or every four weeks).
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news